Switzerland's Galderma falls after UBS cuts rating on limited upside

Galderma AG

30/06/2025 11:39

** Galderma's GALD.S stock slips around 3% after UBS cut its rating on the Swiss skincare company to "neutral" from "buy" citing limited upside

** Brokerage cuts by 6.25% to 120 Swiss francs per share

** Flags weaker outlook for fillers and biostimulators, and higher promotional spending across the segment

** Galderma's Q2 sales forecast for eczema medicine Nemluvio is 18% ahead of consensus, while its injectable aesthetics segment is expected to be 2% below consensus, according to UBS estimates

** "At 2Q (24 July) we expect strong neuromodulators growth offset by a normalisation of 1H aesthetic trends," UBS says

** The stock is at the bottom of Switzerland's mid-caps index .SMIM

 (Reporting by Tristan Veyet)

 ((Tristan.chabba@thomsonreuters.com))